CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Hydroxyurea +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00568698
NCT00568698Phase 2Completed
CompareCT.gov

A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients

Stanford University·interventional·Posted Dec 6, 2007·Updated Oct 2, 2019

In Brief

A Phase 2 clinical trial evaluating Hydroxyurea and Placebo to match hydroxyurea for Muscular Atrophy, Spinal. Completed, enrolled 29 participants across 1 site.

Detailed Summary

The objectives of this trial are: to establish a safety profile for use of Hydroxyurea in children with Type I Spinal Muscular Atrophy; to identify reliable outcome measures for HU treatment in Type I SMA; and to detect the clinical efficacy of HU treatment in children with Type I SMA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMuscular Atrophy, Spinal
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 6, 2007
Enrollment StartJan 1, 2004
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 18.6 years ago

Interventions

Hydroxyureadrug

Placebo to match hydroxyureadrug